Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (171-180 of 264) with videos related to

Pageof 27
Sort By:
Annals of Surgical Oncology|April 12, 2011
Sentinel lymph node biopsy in multicentric breast cancer: five-year results in a large series from a single institutionOreste Gentilini, Paolo Veronesi, Edoardo Botteri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2011
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyMarco Colleoni, Anita Giobbie-Hurder, Meredith M Regan, et al.
British Journal of Cancer|July 16, 2019
Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclinesElisabetta Munzone, Vincenzo Bagnardi, Giuseppe Campennì, et al.
JAMA Oncology|July 13, 2023
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical TrialElisabetta Munzone, Meredith M Regan, Saverio Cinieri, et al.
The Lancet. Oncology|March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
JCO Precision Oncology|January 24, 2025
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical TrialsStephen J Luen, Lauren C Brown, Courtney T van Geelen, et al.
Iscience|August 18, 2025
Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00Andrea Joaquin Garcia, Takashi Semba, Mattia Rediti, et al.
The Lancet. Oncology|September 10, 2018
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trialViviana Galimberti, Bernard F Cole, Giuseppe Viale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trialMarianne Ewertz, Kathryn P Gray, Meredith M Regan, et al.
Cancer|August 19, 2004
Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patientsRoberto Gennari, Giuseppe Curigliano, Nicole Rotmensz, et al.
Pageof 27

Showing results (171-180 of 264) with videos related to

Sort By:
Pageof 27
Annals of Surgical Oncology|April 12, 2011
Sentinel lymph node biopsy in multicentric breast cancer: five-year results in a large series from a single institutionOreste Gentilini, Paolo Veronesi, Edoardo Botteri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2011
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyMarco Colleoni, Anita Giobbie-Hurder, Meredith M Regan, et al.
British Journal of Cancer|July 16, 2019
Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclinesElisabetta Munzone, Vincenzo Bagnardi, Giuseppe Campennì, et al.
JAMA Oncology|July 13, 2023
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical TrialElisabetta Munzone, Meredith M Regan, Saverio Cinieri, et al.
The Lancet. Oncology|March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
JCO Precision Oncology|January 24, 2025
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical TrialsStephen J Luen, Lauren C Brown, Courtney T van Geelen, et al.
Iscience|August 18, 2025
Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00Andrea Joaquin Garcia, Takashi Semba, Mattia Rediti, et al.
The Lancet. Oncology|September 10, 2018
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trialViviana Galimberti, Bernard F Cole, Giuseppe Viale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trialMarianne Ewertz, Kathryn P Gray, Meredith M Regan, et al.
Cancer|August 19, 2004
Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patientsRoberto Gennari, Giuseppe Curigliano, Nicole Rotmensz, et al.
Pageof 27